Sang Myung Woo1, Jungnam Joo2, So Young Kim3, Sang-Jae Park4, Sung-Sik Han4, Tae Hyun Kim4, Young Hwan Koh4, Seung Hyun Chung5, Yun-Hee Kim6, Hae Moon7, Eun Kyung Hong4, Woo Jin Lee8. 1. Center for Liver Cancer, National Cancer Center, Republic of Korea. Electronic address: wsm@ncc.re.kr. 2. Cancer Biostatistics Branch, Research Institute for National Cancer Control and Evaluation, National Cancer Center, Republic of Korea. 3. Department of Clinical Nutrition, National Cancer Center, Republic of Korea. 4. Center for Liver Cancer, National Cancer Center, Republic of Korea. 5. Rehabilitation Medicine, National Cancer Center, Republic of Korea. 6. Molecular Imaging and Therapy Branch, Research Institute, National Cancer Center, Republic of Korea. 7. Emergency Department, National Cancer Center, Republic of Korea. 8. Center for Liver Cancer, National Cancer Center, Republic of Korea. Electronic address: lwj@ncc.re.kr.
Abstract
BACKGROUND:Weight loss in pancreatic cancer is associated with maldigestion due to pancreatic duct obstruction. Pancreatic exocrine replacement therapy (PERT) may significantly improve fat and protein absorption. OBJECTIVES: This prospective, double-blind, randomized, placebo-controlled phase II trial assessed whether PERT could reduce or prevent weight loss in patients with unresectable pancreatic cancer. METHODS:Sixty seven patients with unresectable pancreatic cancer were randomized to receive enteric coated PERT, consisting of 6-9 capsules of pancreatin (457.7 mg/capsule), or placebo. Patients took two capsules each three times daily during main meals and one capsule each up to three times daily when having between-meal snacks. The primary endpoint was the percentage change in body weight at eight weeks. RESULTS: The mean percentage change in body weight (1.49% [1.12 kg] vs. 2.99% [1.63 kg], P = 0.381) and the mean percent change in Patient-Generated Subjective Global Assessment (PG-SGA) score (8.85% vs. 15.69%, p = 0.18) did not differ significantly between the PERT and placebo groups. There was no improvement in quality of life and overall survival did not differ significantly between the PERT and placebo groups (5.84 months vs 8.13 months, p = 0.744). CONCLUSIONS:PERT did not reduce weight loss in patients with unresectable pancreatic cancer. Larger randomized trials are needed to identify those patients who may benefit from PERT. TRIAL REGISTRATION: ClinicalTrials.gov Number NCT01587534.
RCT Entities:
BACKGROUND:Weight loss in pancreatic cancer is associated with maldigestion due to pancreatic duct obstruction. Pancreatic exocrine replacement therapy (PERT) may significantly improve fat and protein absorption. OBJECTIVES: This prospective, double-blind, randomized, placebo-controlled phase II trial assessed whether PERT could reduce or prevent weight loss in patients with unresectable pancreatic cancer. METHODS: Sixty seven patients with unresectable pancreatic cancer were randomized to receive enteric coated PERT, consisting of 6-9 capsules of pancreatin (457.7 mg/capsule), or placebo. Patients took two capsules each three times daily during main meals and one capsule each up to three times daily when having between-meal snacks. The primary endpoint was the percentage change in body weight at eight weeks. RESULTS: The mean percentage change in body weight (1.49% [1.12 kg] vs. 2.99% [1.63 kg], P = 0.381) and the mean percent change in Patient-Generated Subjective Global Assessment (PG-SGA) score (8.85% vs. 15.69%, p = 0.18) did not differ significantly between the PERT and placebo groups. There was no improvement in quality of life and overall survival did not differ significantly between the PERT and placebo groups (5.84 months vs 8.13 months, p = 0.744). CONCLUSIONS:PERT did not reduce weight loss in patients with unresectable pancreatic cancer. Larger randomized trials are needed to identify those patients who may benefit from PERT. TRIAL REGISTRATION: ClinicalTrials.gov Number NCT01587534.
Authors: Daniel de la Iglesia; Bartu Avci; Mariia Kiriukova; Nikola Panic; Maryana Bozhychko; Vasile Sandru; Enrique de-Madaria; Gabriele Capurso Journal: United European Gastroenterol J Date: 2020-07-06 Impact factor: 4.623
Authors: Chris E Forsmark; Gong Tang; Hongzhi Xu; Marie Tuft; Steven J Hughes; Dhiraj Yadav Journal: Aliment Pharmacol Ther Date: 2020-04-06 Impact factor: 8.171
Authors: William Paul Skelton; Hiral Parekh; Jason S Starr; Jose Trevino; Jessica Cioffi; Steven Hughes; Thomas J George Journal: J Gastrointest Cancer Date: 2018-03
Authors: Miroslav Vujasinovic; Roberto Valente; Marco Del Chiaro; Johan Permert; J-Matthias Löhr Journal: Nutrients Date: 2017-02-23 Impact factor: 5.717
Authors: Vikesh K Singh; Mark E Haupt; David E Geller; Jerry A Hall; Pedro M Quintana Diez Journal: World J Gastroenterol Date: 2017-10-21 Impact factor: 5.742
Authors: Mary E Phillips; Andrew D Hopper; John S Leeds; Keith J Roberts; Laura McGeeney; Sinead N Duggan; Rajesh Kumar Journal: BMJ Open Gastroenterol Date: 2021-06
Authors: Juan Enrique Domínguez-Muñoz; Laura Nieto-Garcia; Javier López-Díaz; Jose Lariño-Noia; Ihab Abdulkader; Julio Iglesias-Garcia Journal: BMC Cancer Date: 2018-05-05 Impact factor: 4.430